白蛋白結(jié)合型紫杉醇治療晚期耐藥復(fù)發(fā)卵巢癌的療效及安全性
發(fā)布時(shí)間:2018-03-08 08:52
本文選題:白蛋白 切入點(diǎn):紫杉醇 出處:《中國老年學(xué)雜志》2017年16期 論文類型:期刊論文
【摘要】:目的探討白蛋白結(jié)合型紫杉醇(nab-p)治療晚期耐藥復(fù)發(fā)卵巢癌的療效及耐受性。方法對2012年1月至2015年12月在吉林大學(xué)第一醫(yī)院接受以nab-p為基礎(chǔ)化療方案的21例復(fù)發(fā)/難治性晚期卵巢癌患者進(jìn)行回顧性臨床分析。均為經(jīng)多線藥物治療后復(fù)發(fā)的患者,給予nab-p 120 mg/m2,第1、8天,聯(lián)合或不聯(lián)合卡鉑[卡鉑曲線下面積(AUC)=4~5,第2天]靜脈滴注,21 d為1個(gè)療程。結(jié)果 21例患者均可評估療效,無完全緩解病例,部分緩解13例,疾病穩(wěn)定5例,疾病進(jìn)展3例。21例患者接受nab-p為基礎(chǔ)化療方案的有效率為61.9%(13/21),CA125完全緩解率為28.6%(6/21);鉑類敏感者的有效率為88.9%(8/9),鉑類耐藥者的有效率為41.6%(5/12),兩者差異無統(tǒng)計(jì)學(xué)意義(P0.05)。治療過程中1例出現(xiàn)了肝功能1級異常,2例出現(xiàn)了2級粒細(xì)胞減少不伴發(fā)熱,2例出現(xiàn)Ⅱ度外周神經(jīng)病變。未記錄到劑量減少或治療中斷。結(jié)論 nab-p在先前接受過多線藥物治療的復(fù)發(fā)/難治性卵巢癌患者中表現(xiàn)出較好的療效性及耐受性。
[Abstract]:Objective to investigate the efficacy and tolerance of albumin binding taxol nab-p in the treatment of advanced drug-resistant recurrent ovarian cancer. Methods from January 2012 to December 2015, 21 patients received chemotherapy based on nab-p in Jilin University first Hospital. / retrospective clinical analysis of patients with refractory advanced ovarian cancer. Nab-p 120 mg / m ~ (2), day 1 ~ 8, combined or not carboplatin [area under carboplatin curve] intravenously dripping for 21 days was a course of treatment. Results 21 patients could evaluate the curative effect, none of them had complete remission, 13 had partial remission. The disease was stable in 5 cases, The effective rate of nab-p based chemotherapy regimen was 61.9%, and the complete remission rate of CA125 was 28.66.21%. The effective rate of platinum-sensitive patients was 88.9% and that of platinum-resistant patients was 41.6% / 122.There was no significant difference between the two groups in the course of treatment. Grade 1 abnormal liver function was found in 1 case and grade 2 granulocytopenia without fever occurred in 2 cases. No dose reduction or interruption of treatment was recorded in 2 cases. Conclusion nab-p was previously given multiple line drugs. Treatment of recurrent / refractory ovarian cancer patients showed good efficacy and tolerance.
【作者單位】: 吉林大學(xué)第一醫(yī)院腫瘤中心;
【分類號(hào)】:R737.31
【相似文獻(xiàn)】
相關(guān)期刊論文 前1條
1 曾靖;張蓉;;白蛋白結(jié)合型紫杉醇在婦科腫瘤中的研究進(jìn)展[J];國際婦產(chǎn)科學(xué)雜志;2014年03期
,本文編號(hào):1583207
本文鏈接:http://sikaile.net/yixuelunwen/fuchankeerkelunwen/1583207.html
最近更新
教材專著